DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,603.796 B2 Lichter Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,603.796 B2 Lichter Et Al US0096.03796 B2 (12) United States Patent (10) Patent No.: US 9,603.796 B2 Lichter et al. (45) Date of Patent: *Mar. 28, 2017 (54) CONTROLLED RELEASE ANTIMICROBIAL A63L/43 (2006.01) COMPOSITIONS AND METHODS FOR THE A6II 3/522 (2006.01) TREATMENT OF OTC DISORDERS A 6LX 3/573 (2006.01) A63L/7036 (2006.01) (71) Applicants: Otonomy, Inc., San Diego, CA (US); (52) U.S. Cl The R ts of the University of AV e. we (NEON y O CPC .......... A61K 9/0046 (2013.01); A61K 9/0019 s s (2013.01); A61K 9/0024 (2013.01); A61K 9/06 (72) Inventors: Jay Lichter, San Diego, CA (US); (2013.01); A61K 9/10 (2013.01); A61K 9/1641 Andrew M. Trammel, Olathe, KS (2013.01); A61K 31/43 (2013.01); A61 K (US); Fabrice Piu, San Diego, CA 3 1/496 (2013.01); A61 K3I/522 (2013.01); (US); Qiang Ye, San Diego, CA (US); A6 IK3I/573 (2013.01); A61K 3 1/7036 Luis A. Delianary, San Marcos, CA (2013.01); A61K 47/02 (2013.01); A61K 47/10 (US); Carl Lebel Malibu CA (US); (2013.01); A61K 47/34 (2013.01); A6 IK 8/042 Jeffrey P. Harris, La Jolla, CA (US) (2013.01); A61 K 9/14 (2013.01) (58) Field of Classification Search (73) Assignees: OTONOMY, INC., San Diego, CA CPC ... A61K 31/43; A61K 31/496; A61K 31/522; (US): THE REGENTS OF THE A61K 3 1/573; A61K 3 1/7036; A61 K UNIVERSITY OF CALIFORNIA, 47/02: A61K 47/10; A61K 47/34: A61 K Oakland, CA (US) 8/042: A61 K9/0019; A61K 9/0024; A61 K9/0046; A61K 9/06; A61 K9/10: (*) Notice: Subject to any disclaimer, the term of this A61K 9/14: A61 K 9/1641 patent is extended or adjusted under 35 See application file for complete search history. U.S.C. 154(b) by 0 days. This patent is Subject to a terminal dis- (56) References Cited claimer. U.S. PATENT DOCUMENTS (21) Appl. No.: 14/836,184 4,188,373 A 2, 1980 Krezanoski (22) Filed: Aug. 26, 2015 4,268,519 A 5/1981 Turner 4,478,822 A 10, 1984 Haslam et al. (65) Prior Publication Data 4,938,763. A 7, 1990 Dunn et al. 4,968,507 A 11/1990 Zentner et al. US 2016/0051547 A1 Feb. 25, 2016 (Continued) Related U.S. Application Data FOREIGN PATENT DOCUMENTS (63) Continuation of application No. 13/645,126, filed on CN 101664381 A 3, 2010 Oct. 4, 2012, now Pat. No. 9,233,068, which is a EP O551626 A1 7, 1993 continuation of application No. 12/506,127, filed on (Continued) Jul. 20, 2009, now Pat. No. 8,318,817, and a continuation-in-part of application No. 12/427,663, OTHER PUBLICATIONS filed on Apr. 21, 2009, now Pat. No. 9,132,087, and a continuation-in-part of application No. 12/466,310, PCT/US2014/052754 International Preliminary Report on Patent filed on May 14, 2009, now Pat. No. 8,030,297. ability dated Mar. 10, 2016. (60) Provisional application No. 61/082,450, filed on Jul. (Continued) 21, 2008, provisional application No. 61/082,871, filed on Jul. 23, 2008, provisional application No. 61/094,384, filed on Sep. 4, 2008, provisional Primary Examiner — Sarah Pihonak application No. 61/101,112, filed on Sep. 29, 2008, (74) Attorney, Agent, or Firm — Wilson, Sonsini, provisional application No. 61/140,033, filed on Dec. Goodrich & Rosati 22, 2008. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) Disclosed herein are compositions and methods for the A6 IK 9/10 (2006.01) treatment of otic diseases or conditions with antimicrobial A6 IK 9/16 (2006.01) agent compositions and formulations administered locally to A6 IK 9/06 (2006.01) an individual afflicted with an otic disease or condition, A6 IK 9/14 (2006.01) through direct application of these compositions and formu A6 IK 8/04 (2006.01) lations onto or via perfusion into the targeted auris A6 IK 47/34 (2006.01) structure(s). A6 IK 3/496 (2006.01) A6 IK 47/02 (2006.01) A6 IK 47/10 (2006.01) 8 Claims, 5 Drawing Sheets US 9,603.796 B2 Page 2 (56) References Cited 2008/O103118 A1 5/2008 Clement et al. 2008/O124385 A1 5/2008 Campbell U.S. PATENT DOCUMENTS 2008. O181952 A1 7/2008 Vogel et al. 2008/0318918 A1 12/2008 Campbell et al. 5,033,252 A 7, 1991 Carter 2009/0093449 A1 4/2009 Bowman et al. 5,052,558 A 10, 1991 Carter 2009, O156566 A1 6, 2009 Wall et al. 5,292,516 A 3/1994 Viegas et al. 2009/0246255 A1 10/2009 Meyer 5,323,907 A 6, 1994 Kalvelage 2009/0325938 A1 12/2009 Lichter et al. 5,324,519 A 6, 1994 Dunn et al. 2010, OO16218 A1 1/2010 Lichter et al. 5,401,741 A 3, 1995 Sato et al. 2010, OO16450 A1 1/2010 Lichter et al. 5,421,818 A 6, 1995 Arenberg 2010, 0021416 A1 1/2010 Lichter et al. 5,474,529 A 12, 1995 Arenberg 2010, O197800 A1 8/2010 Friedman et al. 5,476,446 A 12/1995 Arenburg 2010/0273864 A1 10, 2010 Lichter et al. 5.503,848 A 4, 1996 Perbellini et al. 2011 0166060 A1 7, 2011 Simons et al. 570276 A 12/1997 Dunn et al. 2011/03.19377 A1 12/2011 Lichter et al. 5,744,153 A 4, 1998 Yewey et al. 2012,0277199 A1 11/2012 Ye et al. 5.861,174 A 1/1999 Stratton et al. 2013/011621.0 A1 5, 2013 Lichter et al. 5.990.194 A 11/1999 Dunn et al. 2013/0216609 A1 8, 2013 Lichter et al. 6004573 A 12/1999 Rathi et al. 2014/0364403 A1 12/2014 Lichter et al. 6,045,528 A 4/2000 Arenberg et al. 2015. O150798 A1 6/2015 Gupta et al. 6,117,949 A 9, 2000 Rathi et al. 6,139,870 A 10, 2000 Verrecchia FOREIGN PATENT DOCUMENTS 6,177,434 B1 1/2001 Kopke et al. 6,201,065 B1 3, 2001 Pathak et al. EP 2567710 A1 3, 2013 6,201,072 B1 3, 2001 Rathi et al. JP HO1258620 A 10, 1989 6,239,113 B1 5, 2001 Dawson et al. JP HO7215877 A 8, 1995 6,284.804 B1 9/2001 Singh et al. JP 2001520188 A 10, 2001 6,287,588 B1 9, 2001 Shih et al. JP 2004507450 A 3, 2004 6,316,011 B1 11/2001 Ron et al. JP 200453.6836. A 12/2004 6,359,016 B2 3/2002 Singh et al. JP 2006097O31 A 4/2006 6,392,036 B1 5/2002 Karlsson et al. JP 2006111585 A 4/2006 6,488,952 B1 12/2002 Kennedy et al. JP 2011518195 A 6, 2011 6,509,327 B1 1/2003 Cagle et al. WO WO-973.8698 A1 10, 1997 6,589,549 B2 7/2003 Shih et al. WO WO-9920261 A2 4f1999 6,649,621 B2 11/2003 Kopke et al. WO WO-9924051 A2 5, 1999 6,740,664 B2 5/2004 Cagle et al. WO WO-9932151 A1 7, 1999 7,001,615 B1 2/2006 Singh et al. WO WO-9932 152 A2 7/1999 7,018,645 B1 3, 2006 Piao et al. WO WO-OOO7603 A2 2, 2000 7,220,431 B2 5, 2007 Sawchuk et al. WO WO-0050005 A1 8, 2000 7,524,834 B2 4/2009 Karlsson et al. WO WO-O 176558 A1 10/2001 8,030,297 B2 10/2011 Lichter et al. WO WO-02056890 A1 T 2002 8,318,817 B2 11/2012 Lichter et al. WO WO O3005961 A2 1, 2003 8,349,353 B2 1/2013 Lichter et al. WO WO-03017990 A2 3, 2003 8,390,018 B2 3/2013 Jang WO WO-O3O34979 A2 5, 2003 8,399,018 B2 3/2013 Lichter et al. WO WO-03051375 A1 6, 2003 8,496.957 B2 7, 2013 Lichter et al. WO WO-03071986 A2 9, 2003 8,648, 119 B2 2/2014 Lichter et al. WO WO-2004.050O21 A2 6, 2004 8,784,870 B2 7, 2014 Lichter et al. WO WO-2006O29074 A2 3, 2006 8,828,980 B2 9, 2014 Lichter et al. WO WO-2006O99325 A2 9, 2006 8,846,770 B2 9, 2014 Lichter et al. WO WO-2006 102964 A2 10, 2006 9,132,087 B2 9, 2015 Lichter et al. WO WO-2007031098 A1 3, 2007 2001/0034339 A1 10/2001 Singh et al. WO WO-2007031280 A2 3, 2007 2002/0022629 A1* 2/2002 Cagle ................... A61K 9.0043 WO WO-2007O34989 A1 3, 2007 514,253.08 WO WO-2007037874 A2 4/2007 2002/0107238 A1 8/2002 Bandyopadhyay et al. WO WO-2007037886 A2 4/2007 2002/0169142 A1 11/2002 Jafari et al. WO WO-2007038949 A1 4/2007 2003/0092776 A1 5, 2003 Ron et al. WO WO 2008.001341 A1 1, 2008 2003. O139382 A1 7, 2003 Wall et al. WO WO-2008073938 A2 6, 2008 2003/0229333 A1 12/2003 Ashton et al. WO WO-2008076556 A2 6, 2008 2004/0022853 A1 2, 2004 Ashton et al. WO WO-20091399.24 A2 11/2009 2004/0082.509 A1 4/2004 Bonny WO WO-2009142719 A2 11/2009 2004/0101506 A1 5, 2004 Fust WO WO-2010011609 A2 1, 2010 2004/0204471 A1 10, 2004 Seibert 2005, 0147585 A1 7, 2005 Schwarz 2005/015.9369 A1* 7, 2005 Lane .....................
Load more

Recommended publications
  • The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1939 The Use of barbital compounds in producing analgesia and amnesia in labor Stuart K. Bush University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Bush, Stuart K., "The Use of barbital compounds in producing analgesia and amnesia in labor" (1939). MD Theses. 730. https://digitalcommons.unmc.edu/mdtheses/730 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE USE OF THE BARBITAL COMPOUl~DS IN PRODUCING ANALGESIA AND .AMNESIA.IN LABOR Stuart K. Bush Senior Thesis Presented to the College of Medicine, University of Nebraska, Omaha, 1939 481021 THE USE OF THE BARBITAL COMPOUNDS IN PROLUCING ANALGESIA AND AMNESIA IN LABOR The Lord God said unto Eve, "I will greatly mul­ tiply thy sorrow and thJ conception; in sorrow thou shalt bring forth children." Genesis 3:lti Many a God-fearing man has held this to mean that any attempt to ease the suffering of the child­ bearing mother would be a direct violation of the Lord's decree. Even though the interpretation of this phrase has formed a great barrier to the advance­ ment of the practice of relieving labor pains, attempts to achieve this beneficent goal have been made at va­ rious times throughout the ages.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,124,126 B2 Bosse Et Al
    USOO81241.26B2 (12) United States Patent (10) Patent No.: US 8,124,126 B2 BOSse et al. (45) Date of Patent: Feb. 28, 2012 (54) PHARMACEUTICAL COMPOSITIONS (58) Field of Classification Search ........................ None See application file for complete search history. (75) Inventors: Paul Bosse, Charleston, SC (US); John Ameling, Cincinnati, OH (US); Bernard (56) References Cited Schachtel, Jupiter, FL (US); Ray Takigiku, Loveland, OH (US) U.S. PATENT DOCUMENTS 4,113,866 A 9, 1978 Lednicer et al. (73) Assignee: Charleston Laboratories, Inc., (Continued) Charleston, SC (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this CA 2665841 10/2007 patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 12/351,704 OTHER PUBLICATIONS Alexander, etal. Comparison ofondansetron and droperidol in reduc (22) Filed: Jan. 9, 2009 ing postoperative nausea and vomiting associated with patient-con trolled analgesia. Anaesthesia. Dec. 1995:50(12): 1086-8. (65) Prior Publication Data (Continued) US 2009/O175939 A1 Jul. 9, 2009 Primary Examiner — Susan Tran Related U.S. Application Data (74) Attorney, Agent, or Firm — Wilson Sonsini Goodrich & (60) Provisional application No. 61/020,139, filed on Jan. Rosati 9, 2008, provisional application No. 61/043,037, filed on Apr. 7, 2008, provisional application No. (57) ABSTRACT 61/060,758, filed on Jun. 11, 2008. Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including (51) Int. Cl. reducing or eliminating an adverse effect associated with the A6 IK9/20 (2006.01) analgesic. A6 IK9/24 (2006.01) (52) U.S.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter Et Al
    USOO9205048B2 (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter et al. (45) Date of Patent: *Dec. 8, 2015 (54) CONTROLLED RELEASE ANTIMICROBIAL (58) Field of Classification Search COMPOSITIONS AND METHODS FOR THE CPC A61 K9/0024; A61 K9/0046; A61K 31/497; TREATMENT OF OTC DSORDERS A61K 47/34 See application file for complete search history. (71) Applicants: Otonomy, Inc., San Diego, CA (US); The Regents of the University of California, Oakland, CA (US) (56) References Cited (72) Inventors: Jay Lichter, Rancho Santa Fe, CA (US); U.S. PATENT DOCUMENTS Andrew M. Trammel, Olathe, KS (US); 4,188,373 A 2, 1980 Krezanoski Fabrice Piu, San Diego, CA (US); 4,478,822 A 10, 1984 Haslam et al. Qiang Ye, San Diego, CA (US); Luis A. 4,938,763. A 7, 1990 Dunn et al. Dellamary, San Marcos, CA (US); Carl 4,968,507 A 11/1990 Zentner et al. 5,033,252 A 7, 1991 Carter Lebel, Malibu, CA (US); Jeffrey P. 5,052,558 A 10, 1991 Carter Harris, La Jolla, CA (US) 5,292,516 A 3/1994 Viegas et al. 5,323,907 A 6/1994 Kalvelage (73) Assignees: OTONOMY, INC., San Diego, CA 5,324,519 A 6/1994 Dunn et al. (US): THE REGENTS OF THE 5,421,818 A 6/1995 Arenberg UNIVERSITY OF CALIFORNLA, 5,474,529 A 12/1995 Arenberg 5,476,446 A 12/1995 Arenberg Oakland, CA (US) 5,503,848 A 4/1996 Perbellini et al. 5,702,716 A 12/1997 Dunn et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,526,704 B2 Bosse Et Al
    USO09526704B2 (12) United States Patent (10) Patent No.: US 9,526,704 B2 BOSse et al. (45) Date of Patent: *Dec. 27, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR A6IR 9/24 (2006.01) TREATING OR PREVENTING PAN A69/20 (2006.01) (52) U.S. Cl. (71) Applicant: LOCL Pharma, Inc., Las Vegas, NV CPC ............. A61K 9/209 (2013.01); A61 K9/2013 (US) (2013.01); A61 K9/2054 (2013.01); A61 K 3 1/167 (2013.01); A61K 31/485 (2013.01); (72) Inventors: Paul Bosse, Jupiter, FL (US); John A61K 3.1/5415 (2013.01) Ameling, Jupiter, FL (US); Bernard (58) Field of Classification Search Schachtel, Jupiter, FL (US); Ray CPC A61K 2300/00; A61K 31/167; A61K 31/485; Takigiku, Loveland, OH (US) A61K 3.1/5415: A61 K9/2054: A61 K 9/209 (73) Assignee: LOCL PHARMA, INC., Las Vegas, See application file for complete search history. NV (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 3,048,526 A 8/1962 Boswell This patent is Subject to a terminal dis- 3,108,046 A 10/1963 Harbit claimer. (Continued) (21) Appl. No.: 15/206.955 FOREIGN PATENT DOCUMENTS 1-1. CA 2262267 A1 8, 1999 (22) Filed: Jul. 11, 2016 DE 102005O13726 A1 9, 2006 (65) Prior Publication Data (Continued) US 2016/0317447 A1 Nov. 3, 2O16 OTHER PUBLICATIONS Related U.S. Application Data US 8.975,271, 03/2015, Oshlack et al.
    [Show full text]
  • Perspectives in Drug Discovery a Collection of Essays on the History and Development of Pharmaceutical Substances
    Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Artillerigatan 12 • SE-587 58 Linköping • Sweden E-mail: [email protected] Internet: www.rmv.se RMV-report 2010:1 ISSN 1103-7660 Copyright © 2010 National Board of Forensic Medicine and Professor Alan Wayne Jones Design and graphic original: Forma Viva, Linköping • Sweden Printed by Centraltryckeriet, Linköping • Sweden, October 2010 Contents Preface Introduction 1. The First Sedative Hypnotics . 13 2. The Barbiturates ......................... 19 3. The Benzodiazepines ..................... 25 4. Narcotic Analgesics . 31 5. Central Stimulant Amines . 39 6. The First Antidepressants .................. 45 7. Antipsychotic Medication ................. 51 8. Aspirin and Other NSAID .................. 59 9. General Anesthetics . 65 10. SSRI Antidepressants . 71 11. Histamine Antagonists .................... 79 12. Anticonvulsants ......................... 87
    [Show full text]
  • Wo 2009/132050 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 October 2009 (29.10.2009) WO 2009/132050 A2 (51) International Patent Classification: 61/101,1 12 29 September 2008 (29.09.2008) US A61K 39/395 (2006.01) A61K 47/34 (2006.01) 61/140,033 22 December 2008 (22. 12.2008) US A61P 27/16 (2006.01) A61K 9/06 (2006.01) 61/160,233 13 March 2009 (13.03.2009) US (21) International Application Number: (71) Applicants (for all designated States except US): OTON- PCT/US2009/041320 OMY, INC. [US/US]; 5626 Oberlin Drive, Suite 100, San Diego, CA 92121 (US). THE REGENTS OF THE (22) International Filing Date: UNIVERSITY OF CALIFORNIA [US/US]; 1111 2 1 April 2009 (21 .04.2009) Franklin Street, 12th Floor, Oakland, CA 94607 (US). (25) Filing Language: English (72) Inventors; and (26) Publication Language: English (75) Inventors/Applicants (for US only): LICHTER, Jay [US/US]; P.O. Box 676244, Rancho Santa Fe, CA 92067 (30) Priority Data: (US). VOLLRATH, Benedikt [DE/US]; 4704 Niagara 61/046,543 2 1 April 2008 (21 .04.2008) US Avenue, San Diego, CA 92107 (US). TRAMMEL, An¬ 61/048,878 29 April 2008 (29.04.2008) US drew, M. [US/US]; 12485 South Alden Circle, Olathe, 61/127,7 13 14 May 2008 (14.05.2008) us KS 66062 (US). DURON, Sergio, G. [US/US]; 1605 61/055,625 23 May 2008 (23.05.2008) us Neale Street, San Diego, CA 92103 (US).
    [Show full text]
  • Phytochemical Study and Anticancer Potential of High Antioxidant Australian Native Plants
    Phytochemical Study and Anticancer Potential of High Antioxidant Australian Native Plants Author Sirdaarta, Joseph P Published 2016 Thesis Type Thesis (PhD Doctorate) School School of Natural Sciences DOI https://doi.org/10.25904/1912/1565 Copyright Statement The author owns the copyright in this thesis, unless stated otherwise. Downloaded from http://hdl.handle.net/10072/365567 Griffith Research Online https://research-repository.griffith.edu.au Griffith University Phytochemical study and anticancer potential of high antioxidant Australian native plants Principal supervisor: Dr Ian Edwin Cock Co-supervisor: Dr Sarah Ashmore By Joseph P Sirdaarta B. Food Science and Nutrition (Hons) School of Natural Sciences Griffith University Submitted in fulfilment of the requirements of the degree of Doctor of Philosophy On the April 11th 2016 Chapter 1 1 | P a g e Statement of Originality This work, entitled Phytochemical study and anticancer potential of high antioxidant Australian native plants, has not previously been submitted for a degree in any university. To the best of my knowledge and belief, the thesis contains no material previously published or written by another person except where due reference is made in the thesis itself. Joseph P Sirdaarta April 11th, 2016 Chapter 1 2 | P a g e Acknowledgements I would like to take this opportunity to thank the Lord Jesus Christ for giving me this opportunity to pursue my PhD. He has all my gratitude for his provisions and support through trying times. Furthermore, I would like to thank Griffith University for offering me the opportunity through scholarships to complete the program. I would like to thank my supervisors Dr Ian Cock and Dr Sarah Ashmore for their help and guidance.
    [Show full text]
  • Thermotropic Icy Road Sign with Light Scattering and Fluorescence Response
    Thermotropic Icy Road Sign with Light Scattering and Fluorescence Response a a a a Received 8th April 2021, Joshua R. Booth,† Robert A. Young,† Andrés N. Richards Gonzales, Zachary J. Meakin, Corinna M. Preuss-Weber,a,b Ross W. Jaggersa and SteFan A. F. Bon*a Prototypes of flexible, electricity-free, ice warning signs for roads and pavements have been developed. A thermotropic response in the form of an upper critical solution (UCST) type phase separation targeted near the freezing point of water manifests itself through light scattering as a clear-to-opaque transition. It is simultaneously amplified by an enhanced photoluminescence effect. The conceptual road sign application is a multi-lamellar flexible strip with an active layer of a polystyrene-based solution. The solvent is a plasticizer, here either dioctylphthalate (DOP) or its alternative 1,2-cyclohexane dicarboxylic acid diisononyl ester (DINCH). A collection of styrene-based macromolecules were made by free radical (co)polymerization, varying molecular weight and monomer feed composition. UCST type phase diagrams for the polymer solutions were constructed from cloud point data measured by a bespoke photographic set-up, in which up to 30 samples were measured simultaneously using both light scattering, that is opacity, and fluorescence. For the latter, the concept of restricted motion enhanced photoluminescence, often referred to as aggregation-induced emission (AIE), was used. Polystyrene labelled with tetraphenylethylene (TPE) was used for this. The contrast between ‘ON’ and ‘OFF’ states in the protoype ice warning signs was optimized by tuning the polymer concentration and the active layer thickness. Our prototype signs show full reversibility over many temperature cycles.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.433,625 B2 Bosse Et Al
    USOO9433625B2 (12) United States Patent (10) Patent No.: US 9.433,625 B2 BOSse et al. (45) Date of Patent: *Sep. 6, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR (52) U.S. Cl. TREATING OR PREVENTING PAN CPC ........... A61K 3.1/5415 (2013.01); A61K 9/209 - - - (2013.01); A61 K9/2054 (2013.01); A61 K (71) Applicant: 19. Pharma, Inc., Las Vegas, NV 31/167 (2013.01); A61K 31/485 (2013.01) (58) Field of Classification Search (72) Inventors: Paul Bosse, Jupiter, FL (US); John CPC ........... A61K 2300/00; A61K 31/167: A61 K Ameling, Cincinnati, OH (US); 31/485; A61K 3.1/5415: A61 K9/2054; Bernard Schachtel, Jupiter, FL (US); A61 K9/209 Ray Takigiku, Loveland, OH (US) See application file for complete search history. (73) Assignee: LOCL PHARMA, INC., Las Vegas, (56) References Cited NV (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 3,048,526 A 8, 1962 Boswell U.S.C. 154(b) by 0 days. 3,108,046 A 10, 1963 Harbit This patent is Subject to a terminal dis- (Continued) claimer. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 14/244,455 CA 2262267 A1 8/1999 (22) Filed1C Apr. 3, 2014 DE 102005O13726 A1 9, 2006 pr. 5, (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2014/O3O8349 A1 Oct. 16, 2014 O O U.S. Appl. No. 14/683,886, filed Apr. 10, 2015, Bosse et al. Related U.S. Application Data (Continued) (63) Continuation of application No. 12/967,423, filed on i is: .
    [Show full text]
  • The Barbiturates in Forensic Chemistry Dissertation
    THE BARBITURATES IN FORENSIC CHEMISTRY DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy- in the Graduate School of The Ohio State University EQr GWENDOLYN BERTHA CARSON, B« S., M* A* The Ohio State University 195U Approved by* Department of Physiological Chemistry ___________ i TABLE OP CONTENTS page A« Introduction 1 B» Historical 1. The Barbiturates ---------------- 2 2* Barbiturate Poisoning - - -------------------- U a) Deaths due to Barbiturates in Pour Counties and the United States - - ------ ----- 11 b) Doses of Barbiturates in Grains - - -- - - 16 3* Barbiturate Regulations------- - ------------ 21 C. Isolation of the Barbiturates ----- --- - - --- - 2h D» Qualitative Tests for Barbiturates ----- — - ---- 26 E. Quantitative Methods for Barbiturates -------- 28 F* Examination of Tissues --- — 30 1# Degradation Products of Barbiturates ------ 3 1 2a Percent Recovery of Unchanged Barbiturates - - - 3^ G. Experimental Procedures --------------- 35 1* Effect of 5$ Potassium Hydroxide on Barbiturates- 36 2 . Effect of 20$ Acetic Acid on Barbiturates - - - - 38 3. Effect of Water on Salts of Barbituric Acids - - 38 k» Barbiturates Extracted from Liver with 5$ Potassium Hydroxide - — ___ ip. 5. Barbiturates Extracted from Liver with 20$ Acetic A c i d ------------------------------- Hi 6 . Barbiturates Extracted from Liver at pH 1 0 HU 7. Refractive Indices of Barbiturates - ------- H6 8 . Barbiturate-Cyanide Reaction ---------------- 50 9» Effect of Atmospheric Conditions on Barbiturates-
    [Show full text]
  • 2019 BES/Separation Science Research PI Meeting
    TITLE PAGE Program and Abstracts for the 2019 BES/Separation Science Research PI Meeting Gaithersburg Marriott Washingtonian Center 9751 Washingtonian Boulevard Gaithersburg, Maryland, 20878 September 9 – 11, 2019 The research grants and contracts described in this document are supported by the U.S. Department of Energy, Office of Science/Basic Energy Sciences, as part of the Separation Science Program within the Chemical Sciences, Geosciences and Biosciences Division. i FOREWORD This abstract booklet provides a record of the 2019 U.S. Department of Energy (DOE) contractors’ meeting in Separation Science. This meeting, held at the Marriott Washingtonian Hotel in Gaithersburg, Maryland on September 9 – 11, 2019, was sponsored by the Chemical Sciences, Geosciences and Biosciences Division of the Office of Basic Energy Sciences (BES). The purpose of the meeting was to accelerate research progress through collegial interaction. The objectives of the meeting were to develop a common understanding of researchers' activities at the time of the meeting; to maximize potential for collaborative exchange among research groups; to identify the scientific needs of the research community; and to discuss areas for future research directions. The agenda has oral presentations delivered by a number of the Principle Investigators (PIs), as well as an evening poster session. In this way, all PIs within the BES Separation Science Program presented their most recent work that was supported by the program. With ample time for discussion and interactions, this meeting was focused on the exchange of information and building of collaborations; rather than a formal review of researchers’ achievements or a forum to deliberate and choose future directions for the program.
    [Show full text]
  • Selective Reaction Monitoring (SRM) Daten Von Xenobiotika Für Aufbau Und Validierung Von LC-MS/MS Analysen – Teil 2
    Toxichem Krimtech 2010;77(2):117 Selective Reaction Monitoring (SRM) Daten von Xenobiotika für Aufbau und Validierung von LC-MS/MS Analysen – Teil 2 Stefanie Schröfel, Brunhilde Güssregen, Annika Werle, Markus Nauck, Torsten Arndt Bioscientia Institut für Medizinische Diagnostik GmbH, Konrad-Adenauer-Str. 17, 55218 Ingelheim; e-mail: [email protected] In Fortführung unserer Zusammenstellung von Single Reaction Monitoring (SRM)-Daten von ca. 900 Xenobiotika (Toxichem Krimtech 2008;75(3):149-174) listen wir nachfolgend SRM zu weiteren ca. 820 Substanzen auf. Diese SRM wurden wie zuvor beschrieben durch eigene Tune-Experimente an einem TSQ Quantum Ultra (ThermoFisher) ermittelt oder aus dem In- ternet und der Literatur zusammen getragen. Mit der vorliegenden Erweiterung enthält die Datenbank SRM-Einträge zu ca. 1700 Substanzen. Sie sollte damit ein noch aussagekräftige- res Hilfsmittel sein bei Aufbau und Validierung von LC-MS/MS-Analysemethoden (z. B. Er- kennung isobarer Massenübergänge von Substanzen mit gleicher Retentionszeit) und bei Tandem-Massenspektrometrie-basierten toxikologischen Suchanalysen bei konkretem Ver- giftungsverdacht aber Fehlen von Referenzsubstanzen zur SRM-Ermittlung. Ein Beispiel für die Nützlichkeit einer solchen SRM-Sammlung ist der im vorangehenden Heft (Toxichem Krimtech 2010;77(1):23-28) beschriebene Fall eines „Krypton“-Kräuter- mischungs-Missbrauchs durch eine Opiatabhängige in der stationären Entwöhnungstherapie. Laut Anbieter im Internet enthält diese Räuchermischung, die weniger geraucht, sondern vor- rangig als Teeaufguss getrunken wird, Blätter des Kratombaumes (Mitragyna speciosa). Ein Hauptalkaloid der Kratombaumblätter ist Mitragynin. Mitragynin war für uns als Reinsub- stanz zeitnah nicht verfügbar. Dennoch konnten wir Mitragynin im Urin der Patientin nach- weisen, in dem wir die unten in der Tabelle gelisteten 3 SRM für Mitragynin in unserer LC- MS/MS-Multi-Target-Analyse verwendeten.
    [Show full text]